Adar1 Capital Management, Llc Acquires 10,200 Shares of Rallybio (NASDAQ:RLYB) Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc bought 10,200 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was purchased at an average cost of $13.98 per share, with a total value of $142,596.00. Following the purchase, the insider owned 926,352 shares of the company’s stock, valued at $12,950,400.96. This represents a 1.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, May 18th, Adar1 Capital Management, Llc acquired 6,009 shares of Rallybio stock. The stock was bought at an average price of $13.98 per share, for a total transaction of $84,005.82.
• On Friday, May 15th, Adar1 Capital Management, Llc acquired 300 shares of Rallybio stock. The shares were bought at an average cost of $13.90 per share, with a total value of $4,170.00.
• On Wednesday, May 13th, Adar1 Capital Management, Llc bought 79,259 shares of Rallybio stock. The shares were purchased at an average price of $13.99 per share, with a total value of $1,108,833.41.
• On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The stock was acquired at an average cost of $13.83 per share, with a total value of $11,064.00.
• On Monday, May 11th, Adar1 Capital Management, Llc acquired 50,000 shares of Rallybio stock. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc bought 35,101 shares of Rallybio stock. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The shares were acquired at an average cost of $13.97 per share, with a total value of $1,687,631.88.

Rallybio Trading Up 5.5%

Rallybio stock opened at $15.38 on Friday. The company has a market capitalization of $81.48 million, a price-to-earnings ratio of -3.54 and a beta of -1.10. The business’s fifty day simple moving average is $10.16 and its two-hundred day simple moving average is $7.32. Rallybio Corporation has a 12 month low of $2.16 and a 12 month high of $15.75.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.21 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its stake in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares during the last quarter. Citadel Advisors LLC lifted its stake in shares of Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares during the period. Susquehanna International Group LLP boosted its holdings in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares during the period. Finally, XTX Topco Ltd increased its position in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Analysts Set New Price Targets

RLYB has been the subject of a number of analyst reports. Wall Street Zen raised shares of Rallybio to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Rallybio has an average rating of “Sell”.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.